Abbott Laboratories stock: context after recent performance

Abbott Laboratories (ABT) stock has faced pressure recently, with negative returns over the past week, month, past 3 months, year to date, and past year, drawing investor attention to the company’s fundamentals and valuation.

The recent 7 day share price return of 7.13% and 30 day share price return of 15.26% add to a year to date share price decline of 29.81%. Meanwhile, the 1 year total shareholder return of 33.15% and 5 year total shareholder return of 19.12% point to pressure that has built over time rather than a short term setback.

If recent volatility has you reassessing your watchlist, this can be a good moment to look at other healthcare specialists using our screener for 35 healthcare AI stocks

With Abbott trading at $87.17, alongside an indicated discount to both analyst price targets and intrinsic value estimates, the key question is whether recent weakness has left the stock undervalued or whether the market already reflects its future growth.

Most Popular Narrative: 23.5% Undervalued

At a last close of $87.17 versus a narrative fair value of $113.88, Abbott Laboratories is framed as undervalued, with the story built around diversified healthcare earnings and long term cash flow strength rather than short term market moves.

Abbott’s diversified portfolio (medical devices, diagnostics, nutrition, pharmaceuticals) reduces dependency on any single revenue stream. Innovation in medical devices, particularly the FreeStyle Libre system, supports long-term growth.

Curious what justifies a double digit cash flow based fair value gap, and which revenue and margin paths need to hold up for that to stick, the narrative lays out those assumptions clearly, and also shows how they interact with product mix and global exposure in a way that simple ratios miss.

Result: Fair Value of $113.88 (UNDERVALUED)

However, this story can break if regulatory changes or heavier competition in key products like FreeStyle Libre put pressure on margins and challenge those cash flow assumptions.

Next Steps

With both risks and rewards in play for Abbott, it makes sense to act promptly, review the full picture, and weigh it against your own expectations using our breakdown of 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If Abbott is already on your radar, do not stop there. Broaden your opportunity set and let curated stock ideas work harder for you.

• Target potential mispricings by scanning 51 high quality undervalued stocks, which combine strong fundamentals with prices that may not fully reflect their business quality.
• Strengthen your income stream by reviewing 13 dividend fortresses, designed for investors who want yield supported by resilient businesses.
• Prioritise resilience first by focusing on 72 resilient stocks with low risk scores, which score well on financial stability and business risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.